ep discount back
year
debt total capit
strong beat/rais humira lt trajectori remain overhang
remain neutral rate share despit print describ
strong across-the-board beat manag rais stronger
anticip skyrizi-specif number think myriad pressur point
flagship drug humira ex-u biosimilar pressur newer biolog us includ
skyrizi reform etc could well yet worsen overshadow even best near term
outcom compani diversif effort given despit attract valuat
metric ep dividend yield remain comfort sidelin
strong beat/rais morn report top- bottom-lin beat
non-gaap ep consensu pjc total revenu
consensu pjc beat primarili driven better-than-
fear perform humira vs consensu pjc
expens disciplin opex close consensu though ahead
pjc ep beat precipit ep guidanc rais guid
consensu
bold skyrizi guidanc fda approv skyrizi hand manag
guid revenu contribut weight toward well ahead
consensu pjc acknowledg remiss
rais base recent derm survey work issu bullish guidanc base
confid abil rapidli secur broad formulari coverag aim
commerci access end juli consist survey work acknowledg
slow humira pso like off-set
humira remain vulner face second quarter direct eu biosimilar
competit ex-u humira sale y/i better fear
pjc estimate ex-u guidanc y/i essenti match
expect continu pressur ex-u biosimilar us
market shift altern moa includ skyrizi remain concern
chang number discuss rais skyrizi estim
make chang product estim includ
trim us humira estim consist guidanc increas
venclexta trim orilissa though wonder still
aggress given current run-rat adjust includ opex tweak
bring oper margin line guidanc bring ep
estim guidanc fy ep
continu
commerci regulatori clinic ip risk associ market pipelin product
fulli integr biopharmaceut compani
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
favor sidelin despit decent diversif effort come fruition
skyrizi approv expect upadacitinib approv ex-
us humira revenu current face biosimilar risk us humira revenu face
biosimilar competit year convinc effort pipelin
effort enough overcom humira eros given remain comfort
compani report piper jaffray estim
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
dollar except per share data
row revenu
elotuzumab revenu
total ww elotuzumab revenu
row profit share
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
